Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
One customer — 49% of revenue (nine-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 47% of revenue (three-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 51% of revenue (three-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 50% of revenue (nine-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
Earnings call · FY2019 Q4
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
Filed Feb 20, 2020 · complete as-filed document
SEC periodic report
Filed Mar 6, 2020 · complete as-filed document